Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, NOV. 07, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: TDCOWEN VIRTUALIMMUNOLOGY & INFLAMMATION SUMMIT FIRESIDE CHAT: WEDNESDAY, NOVEMBER 12, 2025, AT 2:30PM ET 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE FIRESIDE CHAT: TUESDAY, DECEMBER 2, 2025, 3:00PM ETLOCATION: MIAMI, FL A LIVE WEBCAST AND ARCHIVED REPLAY OF THE FIRESIDE CHATS WILL BE AVAILABLE ON THE INVESTORS SECTION OF WWW.VORBIO.COM. ABOUT VOR BIO VOR BIO IS A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES.

VOR BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF JEREMY SOKOLOVE, M.D., AS CHIEF MEDICAL OFFICER.

VOR BIO APPOINTS JEREMY SOKOLOVE, M.D. AS CHIEF MEDICAL OFFICER

BOSTON, OCT. 31, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, ON OCTOBER 15, 2025, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 113,478 SHARES OF VOR BIO'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) REPRESENTING THE RIGHT TO RECEIVE AN AGGREGATE OF 24,319 SHARES OF VOR BIO'S COMMON STOCK TO 20 NEWLY HIRED EMPLOYEES. THE FOREGOING STOCK OPTIONS AND RSUS WERE GRANTED AS MATERIAL INDUCEMENTS TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

VOR BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

TELITACICEPT DELIVERED CONSISTENT QUALITY-OF-LIFE IMPROVEMENT ACROSS BOTH TREATMENT AND PLACEBO CROSSOVER ARMS 100% OF PATIENTS ON TELITACICEPT FOR 48 WEEKS ACHIEVED 2-POINT MYASTHENIA GRAVIS ACTIVITIES OF DAILY LIVING (MG-ADL) IMPROVEMENT, WITH A MEAN REDUCTION OF -7.5 POINTS SUSTAINED EFFICACY AND FAVORABLE SAFETY EXTENSION DATA SUPPORT POTENTIAL GLOBAL BEST-IN-DISEASE PROFILE IN GENERALIZED MYASTHENIA GRAVIS (GMG) BOSTON, OCT. 29, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ITS COLLABORATOR, REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), PRESENTED 48-WEEK OPEN-LABEL EXTENSION (OLE) DATA FROM ITS PHASE 3 STUDY IN CHINA EVALUATING TELITACICEPT IN PATIENTS WITH GMG. THE RESULTS WILL BE PRESENTED IN A LATE-BREAKING SESSION ON OCTOBER 29 AT 10:50AM PT AT THE AMERICAN ASSOCIATION OF NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE (AANEM) ANNUAL MEETING.

TELITACICEPT DEMONSTRATES SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE IN 48-WEEK CHINA PHASE 3 OPEN-LABEL EXTENSION GENERALIZED MYASTHENIA GRAVIS DATA

CAMBRIDGE, MASS., OCT. 22, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, ANNOUNCED TODAY THAT IT WILL HOST A LIVE WEBCAST TO PRESENT AND DISCUSS THE NEWLY DISCLOSED, LATE-BREAKING 48-WEEK PHASE 3 CLINICAL DATA IN CHINA FOR TELITACICEPT IN PRIMARY SJGREN'S DISEASE. THE STUDY WAS CONDUCTED BY VOR BIO'S COLLABORATOR REMEGEN CO., LTD (HKEX: 9995, SHA: 688331).

VOR BIO TO HOST WEBCAST ON LATE-BREAKING CHINA PHASE 3 TELITACICEPT DATA IN PRIMARY SJGREN'S DISEASE

CAMBRIDGE, MASS., OCT. 17, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT CLINICAL DATA FROM STAGE A OF A PHASE 3 STUDY IN CHINA SPONSORED BY VOR BIO'S COLLABORATOR REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), WHICH EVALUATED TELITACICEPT IN ADULTS WITH IGA NEUROPATHY (IGAN), WILL BE PRESENTED AS A LATE-BREAKING ORAL PRESENTATION AT AMERICAN SOCIETY OF NEPHROLOGY'S (ASN) KIDNEY WEEK 2025 BEING HELD NOV 5-9, 2025, IN HOUSTON, TEXAS.

VOR BIO ANNOUNCES LATE-BREAKING ORAL PRESENTATION OF CHINA PHASE 3 IGA NEPHROPATHY CLINICAL STUDY AT AMERICAN SOCIETY OF NEPHROLOGY'S KIDNEY WEEK 2025

TRIAL MET PRIMARY ENDPOINT ACHIEVING STATISTICALLY SIGNIFICANT IMPROVEMENT IN DISEASE ACTIVITY, WITH 67.1% OF PATIENTS RESPONDING WITH TELITACICEPT VERSUS 32.7% WITH PLACEBO DUAL INHIBITION OF BAFF AND APRIL VALIDATED AS A TRANSFORMATIVE B-CELL APPROACH, HIGHLIGHTING TELITECICEPT'S POTENTIAL AS A DISEASE-MODIFYING THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BOSTON, OCT. 16, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT RESULTS FROM A PHASE 3 STUDY IN CHINA EVALUATING TELITACICEPTIN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SPONSORED BY ITS COLLABORATOR, REMEGEN CO., LTD., (HKEX: 9995, SHA: 688331), WERE PUBLISHED INTHE NEW ENGLAND JOURNAL OF MEDICINE (NEJM).

VOR BIO ANNOUNCES PUBLICATION OF CHINA PHASE 3 STUDY OF TELITACICEPT IN SYSTEMIC LUPUS ERYTHEMATOSUS INTHE NEW ENGLAND JOURNAL OF MEDICINE

TELITACICEPT MET PRIMARY AND ALL SECONDARY ENDPOINTS, DEMONSTRATING CLINICALLY MEANINGFUL IMPROVEMENTS IN DISEASE ACTIVITY VERSUS PLACEBO ~71.8% OF PATIENTS RECEIVING TELITACICEPT 160MG ACHIEVED 3-POINT ESSDAI (EULAR SJGREN'S SYNDROME DISEASE ACTIVITY INDEX) REDUCTION VS 19.3% ON PLACEBO AT 24 WEEKS SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE THROUGH 48 WEEKS SUPPORT POTENTIAL BEST-IN-DISEASE PROFILE IN PRIMARY SJGREN'S DISEASE (PSD) COMPANY EVALUATING TIMING OF GLOBAL PHASE 3 CLINICAL STUDY IN PRIMARY SJGREN'S DISEASE VOR BIO TO HOST A CONFERENCE CALL ON TUESDAY, OCTOBER 28, 2025 AT 4:30PM ET BOSTON, OCT. 14, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ITS COLLABORATOR, REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), REPORTED POSITIVE 48-WEEK RESULTS FROM ITS PHASE 3 STUDY CONDUCTED IN CHINA EVALUATING TELITACICEPT IN PRIMARY SJGREN'S DISEASE. THE STUDY MET ITS PRIMARY ENDPOINT OF CHANGE FROM BASELINE IN ESSDAI AT WEEK 24, AS WELL AS ALL SECONDARY ENDPOINTS, WITH THE TELITACICEPT 160MG DOSE ACHIEVING HIGHLY SIGNIFICANT P VALUES (P

TELITACICEPT DEMONSTRATES CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT IMPACT ON ESSDAI COMPARED TO PLACEBO IN LATE-BREAKING CHINA PHASE 3 RESULTS IN PRIMARY SJGREN'S DISEASE AT ACR 2025

CAMBRIDGE, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, ON SEPTEMBER 19, 2025, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 76,360 SHARES OF VOR BIO'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) REPRESENTING THE RIGHT TO RECEIVE AN AGGREGATE OF 16,361 SHARES OF VOR BIO'S COMMON STOCK TO EIGHT NEWLY HIRED EMPLOYEES. THE FOREGOING STOCK OPTIONS AND RSUS WERE GRANTED AS MATERIAL INDUCEMENTS TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

BOSTON, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT CLINICAL DATA FROM THE PHASE 3 STUDY IN CHINA EVALUATING TELITACICEPT IN ADULTS WITH PRIMARY SJGREN'S DISEASE, A STUDY SPONSORED BY VOR'S COLLABORATOR REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), WILL BE PRESENTED AS A LATE-BREAKING POSTER PRESENTATION AT ACR CONVERGENCE 2025, BEING HELD OCTOBER 24-29, 2025, AT MCCORMICK PLACE IN CHICAGO, ILLINOIS.

VOR BIO ANNOUNCES LATE-BREAKING POSTER PRESENTATION OF PHASE 3 PRIMARY SJGREN'S DISEASE CLINICAL STUDY AT ACR CONVERGENCE 2025

CAMBRIDGE, MASS., SEPT. 23, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF NAVID Z.

VOR BIO APPOINTS NAVID Z. KHAN, PH.D.

YANTAI, CHINA , SEPT. 17, 2025 /PRNEWSWIRE/ -- REMEGEN (688331.SH/09995.HK) ANNOUNCED THAT THE 48-WEEK OPEN-LABEL EXTENSION (OLE) DATA FROM CHINA PHASE III CLINICAL STUDY OF TELITACICEPT (RC18, BRAND NAME: , A BLYS/APRIL DUAL-TARGET FUSION PROTEIN INNOVATIVE DRUG INDEPENDENTLY DEVELOPED BY REMEGEN) FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) WAS SELECTED AS AN ORAL PRESENTATION AT THE 2025 AMERICAN ASSOCIATION OF NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE (AANEM) ANNUAL MEETING.

RESULTS OF CHINA PHASE III CLINICAL STUDY OF TELITACICEPT FOR GENERALIZED MYASTHENIA GRAVIS SELECTED FOR ORAL PRESENTATION AT 2025 AANEM ANNUAL MEETING

CAMBRIDGE, MASS., SEPT. 17, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT 48-WEEK CLINICAL DATA FROM THE PHASE 3 STUDY IN CHINA EVALUATING TELITACICEPT IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS, A STUDY SPONSORED BY VOR'S COLLABORATOR REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), WILL BE PRESENTED AS AN ORAL PRESENTATION AT THE AMERICAN ASSOCIATION OF NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE ANNUAL MEETING, BEING HELD OCTOBER 29 TO NOVEMBER 1, 2025, AT THE HILTON SAN FRANCISCO UNION SQUARE IN SAN FRANCISCO, CALIFORNIA.

VOR BIO ANNOUNCES ORAL PRESENTATION OF 48-WEEK CHINA PHASE 3 GENERALIZED MYASTHENIA GRAVIS CLINICAL STUDY AT AANEM

CAMBRIDGE, MASS., SEPT. 12, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A FIRESIDE CHAT AND HOST VIRTUAL 1X1 INVESTOR MEETINGS AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM.

Vor Biopharma Inc.

VOR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vor Biopharma Inc.

VOR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VOR